Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Total Liabilities (2016 - 2026)

Heron Therapeutics filings provide 16 years of Total Liabilities readings, the most recent being $237.1 million for Q1 2026.

  • On a quarterly basis, Total Liabilities fell 10.27% to $237.1 million in Q1 2026 year-over-year; TTM through Mar 2026 was $237.1 million, a 10.27% decrease, with the full-year FY2025 number at $241.5 million, down 9.47% from a year prior.
  • Total Liabilities hit $237.1 million in Q1 2026 for Heron Therapeutics, down from $241.5 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $266.8 million in Q4 2024 to a low of $232.3 million in Q1 2023.
  • Median Total Liabilities over the past 5 years was $251.7 million (2024), compared with a mean of $250.6 million.
  • Biggest five-year swings in Total Liabilities: surged 117.74% in 2022 and later dropped 10.27% in 2026.
  • Heron Therapeutics' Total Liabilities stood at $237.4 million in 2022, then grew by 8.05% to $256.5 million in 2023, then grew by 4.02% to $266.8 million in 2024, then dropped by 9.47% to $241.5 million in 2025, then decreased by 1.85% to $237.1 million in 2026.
  • The last three reported values for Total Liabilities were $237.1 million (Q1 2026), $241.5 million (Q4 2025), and $234.1 million (Q3 2025) per Business Quant data.